Anti-CD30 monoclonal antibody BerH2

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD30 monoclonal antibody BerH2
Drug Alias NameBerH2 antibody
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedac Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedac Gmbh +[2] 
Active IndicationsN/A
Inactive IndicationsHodgkin Disease

Other Information

ATC CodeN/A
Related LinksN/A